<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03920319</url>
  </required_header>
  <id_info>
    <org_study_id>Brody011</org_study_id>
    <nct_id>NCT03920319</nct_id>
  </id_info>
  <brief_title>Bupropion and Cigarette-Related Cues in Smokers</brief_title>
  <official_title>Effect of Bupropion Treatment on Brain Activation Induced by Cigarette-Related Cues in Smokers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, double-blind, before-after controlled trial to assess changes in regional brain
      activation in response to cigarette-related cues from before to after treatment with
      bupropion (vs placebo).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2004</start_date>
  <completion_date type="Actual">December 31, 2005</completion_date>
  <primary_completion_date type="Actual">December 31, 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, double-blind, before-after controlled trial</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>Matching placebo pills</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Craving ratings</measure>
    <time_frame>8 weeks</time_frame>
    <description>Participants were instructed to respond from 1 (definitely not) to 5 (definitely) on the question, &quot;I crave a cigarette right now&quot;, after viewing video cues.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exhaled carbon monoxide (CO)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Participants were asked to hold their breath for as long as possible, ideally 15 seconds, then to breathe out slowly into the mouthpiece of a CO monitor, aiming to empty the lungs completely.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cigarettes per day</measure>
    <time_frame>8 weeks</time_frame>
    <description>Self-reported number of cigarettes smoked daily during the past 7 days [??]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fagerström Test for Nicotine Dependence (FTND)</measure>
    <time_frame>8 weeks</time_frame>
    <description>The FTND contains six items that evaluate the quantity of cigarette consumption, the compulsion to use, and dependence. The yes/no items are scored from 0 to 1 and multiple-choice items are scored from 0 to 3. The items are summed to yield a total score of 0-10. The higher the total Fagerström score, the more intense is the patient's physical dependence on nicotine.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Smoking</condition>
  <condition>Smoking, Tobacco</condition>
  <arm_group>
    <arm_group_label>Bupropion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants assigned to 150mg of bupropion daily for the first 3 days, followed by titration up to 2 pills daily, separated by 8 hours, for the remaining 8 weeks of treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants assigned to pill placebo daily for the first 3 days, followed by titration up to 2 pills daily, separated by 8 hours, for the remaining 8 weeks of treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupropion</intervention_name>
    <description>Bupropion 150 mg sustained release</description>
    <arm_group_label>Bupropion</arm_group_label>
    <other_name>bupropion HCl</other_name>
    <other_name>Wellbutrin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Treatment-seeking cigarette smoker

          -  Meet DSM-IV criteria for nicotine dependence

          -  Negative result on urine test for drug use during screening

        Exclusion Criteria:

          -  History of any Axis I psychiatric diagnosis other than nicotine dependence

          -  Medical conditions that might affect brain function

          -  Current use of medications that could alter brain function

          -  Pregnancy

          -  Current illicit drug use other than occasional use of marijuana
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
  </eligibility>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 13, 2019</study_first_submitted>
  <study_first_submitted_qc>April 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2019</study_first_posted>
  <last_update_submitted>April 17, 2019</last_update_submitted>
  <last_update_submitted_qc>April 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupropion</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

